Side-effects in women treated with adjuvant endocrine therapy for breast cancer

IF 5.7 2区 医学 Q1 OBSTETRICS & GYNECOLOGY
L.M. Rademaker , R. Gal , A.M. May , M.C.T. Batenburg , F. van der Leij , R.M. Bijlsma , H.M. Verkooijen , A. Doeksen , M.F. Ernst , D.J. Evers , C.C. van der Pol , E.M. Monninkhof
{"title":"Side-effects in women treated with adjuvant endocrine therapy for breast cancer","authors":"L.M. Rademaker ,&nbsp;R. Gal ,&nbsp;A.M. May ,&nbsp;M.C.T. Batenburg ,&nbsp;F. van der Leij ,&nbsp;R.M. Bijlsma ,&nbsp;H.M. Verkooijen ,&nbsp;A. Doeksen ,&nbsp;M.F. Ernst ,&nbsp;D.J. Evers ,&nbsp;C.C. van der Pol ,&nbsp;E.M. Monninkhof","doi":"10.1016/j.breast.2025.104416","DOIUrl":null,"url":null,"abstract":"<div><div>Many women with breast cancer prematurely discontinue adjuvant endocrine therapy, leading to increased mortality. We performed a cross-sectional survey (n = 456) within the Dutch UMBRELLA-cohort to gain insight into the prevalence of side-effects and its association with premature discontinuation. Almost all current endocrine therapy users experienced side-effects (92.7 %), most frequent were vasomotor- and musculoskeletal symptoms. The most reported reason for premature discontinuation was side-effects (88.1 %). Former treatment with chemotherapy was associated with more reported side-effects (97.2 % vs 82.5 %, ORadj 6.31), but less premature discontinuation of endocrine therapy (18.6 % vs 28.6 %, p-value 0.016).</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 104416"},"PeriodicalIF":5.7000,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0960977625000359","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Many women with breast cancer prematurely discontinue adjuvant endocrine therapy, leading to increased mortality. We performed a cross-sectional survey (n = 456) within the Dutch UMBRELLA-cohort to gain insight into the prevalence of side-effects and its association with premature discontinuation. Almost all current endocrine therapy users experienced side-effects (92.7 %), most frequent were vasomotor- and musculoskeletal symptoms. The most reported reason for premature discontinuation was side-effects (88.1 %). Former treatment with chemotherapy was associated with more reported side-effects (97.2 % vs 82.5 %, ORadj 6.31), but less premature discontinuation of endocrine therapy (18.6 % vs 28.6 %, p-value 0.016).
乳腺癌女性辅助内分泌治疗的副作用
许多患有乳腺癌的妇女过早停止辅助内分泌治疗,导致死亡率增加。我们在荷兰的umbrella队列中进行了一项横断面调查(n = 456),以深入了解副作用的发生率及其与过早停药的关系。几乎所有目前的内分泌治疗使用者都有副作用(92.7%),最常见的是血管舒缩和肌肉骨骼症状。过早停药的主要原因是副作用(88.1%)。先前化疗治疗与更多报告的副作用相关(97.2% vs 82.5%, ORadj 6.31),但更少过早停止内分泌治疗(18.6% vs 28.6%, p值0.016)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Breast
Breast 医学-妇产科学
CiteScore
8.70
自引率
2.60%
发文量
165
审稿时长
59 days
期刊介绍: The Breast is an international, multidisciplinary journal for researchers and clinicians, which focuses on translational and clinical research for the advancement of breast cancer prevention, diagnosis and treatment of all stages.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信